I am new to teckstocks but would like to tell everyone about
a company I have been posting on over at investers forum....
its symbol is DIME. It is, so far, UNDISCOVERED buy the institutional
investors. I strongly urge you to read the following and do you own
investigation. You will find everthing above board and accurate.
Aid "Wonder" Drug WF-10---Phase II Clinicals
Dimethaid Research Inc. (905) 415-1446---Symbol DIME
Canadian Dealer Network--call & obtain Investor's Package
Market Cap $ 66 million US
Market Price $ 4.35 CND --$ 3.15 US
Dime's products target significant global markets with
the potential to generate substantial sales and profits.
Aids drug WF-10 Phase II clinical trial results was completed in
cooperation with FDA in advanced Aids patients in Nashville, Tenn
--Phase III to begin in July in US & CND with as many as 400 patients
---Drug has been shown to greatly enhance the immune system---see
May 21, 1996 press release for results--www.newswire.ca symbol
Dime---annual report also has a lot of clinical information and data
---the Phase II results are extremely impressive---WF-10 "supercharges"
the immune system--BTW this drug also has cancer applications
Company has another drug Pennsaid (Dimethaid-D ) Arthritis--
product in Phase 4---owns patents, mfg, mkt and worldwide rights
to DD--huge $ world market-physicians raving Approximately 10%
of the population of the world suffers from arthritis. In 1991
37 million Americans diagnosed with arthritis received 73 million
prescriptions for arthritis medication at a retail value of $ 2.2 billion.
Dime's arthritis product is one in which the medical community
is raving about. Pennsaid is but the first forumulation which the
company intends to develop using its proprietary transdermal
delivery system.
Pennsaid or DD alone could make Dime a great company
but Dime has also the exclusive marketing rights in Canada
for WF10 (aids virus & cancer treatment also). A private German
company worked for fifteen years on WF10, which
is a powerful stimulator of the immune system and has
expended over $ 40 million in R&D. Dime bought & paid
for the exclusive marketing rights in Canada for WF10 and has
potential for expansion of these rights. No other public entity
has any rights to WF10. The private German company owns
patents, mfg, and mkt rights for WF10 & owns about 10 %
of Dime. WF10 has been shown to be highly
effective in controlling the ill-effects of aids virus by
arresting the deterioration of the immune system.
On May 9, 1996, Dime's subsidiary, Femina, announced the
introduction of a new female contraceptive device.
Order Investor Package & research yourself
Company incorporated 1981
Company desires to be NASDAQ or AMEX listed asap
EXCERPT from 5/21/96 news release regarding WF 10:
CLINICAL TRIAL SHOWS IMMUNE MODULATOR
STRENGTHENS RESISTANCE TO AIDS INFECTIONS
"We expect dramatic gains in the fight against HIV, with
WF10 further boosting the body's natural defense
mechanisms."
EXCERPT from 2/23/96 news release regarding Pennsaid:
CLINICAL TRIALS SHOW NEW PRESCRIPTION
DRUG PROVIDES RELIEF FROM ARTHRITIS
''During the trial a significant difference in pain relief was
reported by patients receiving Pennsaid, as compared to placebo,''
said Dr. Carter Thorne, who was involved in the clinical trials of
Pennsaid. ''Pennsaid offers a reasonable alternative to oral NSAIDs
because it is non-systemic and does not appear to lead to adverse
side effects.''
EXCERPT from 5/9/96 news release:
DIMETHAID RESEARCH, INC's FEMINA, INTRODUCES NEW
CONTRACEPTIVE DEVICE
"We are extemely proud to offer this advance in barrier contraceptives,
said Rebecca Keeler, President of Dime. "Numerous studies have found the
product safe, effective and comfortable. Women will have, for the first time,
a device that is easy to insert and remove................."
other news releases : http:www.newswire.ca symbol DIME |
